To Evaluate and compare effect and skin safety of Clobetasol gel (Clobetasol Propionate USP 0.05% w/w) and Clobetasol Cream (Clobetasol Propionate BP 0.05% w/w) in patients with mild to moderate psoriasis
- Conditions
- Health Condition 1: null- mild to moderate Psoriasis
- Registration Number
- CTRI/2013/02/003430
- Lead Sponsor
- Curatio Healthcare Pvt Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 28
1.Voluntary men/women with clinically diagnosed mild to moderate stable, chronic, plaque psoriasis.
2. 2.At least one, discrete, well circumscribed lesion approximately 20 cm2 â?? 80 cm2 on trunk separated from adjacent lesions by at least 3 cms.The same lesion will be tracked through the entire study.
3.Age between 18 â?? 55 years
4.Not on treatment for psoriasis- oral since 1 month and topical since 2 weeks.
5.Accepting not to use products with the same end benefit during the entire study duration.
6.Cooperating, informed of the need and duration of the examinations, and ready to comply with protocol procedures.
7.Having signed a Consent Form and will be informed orally and in writing of all information concerning the study procedures and study objectives.
1.Pustular psoriasis, Palmoplanter and erythrodermic psoriasis.
2.Pregnant women (as confirmed by UPT) and lactating women.
3.History of allergic dermatitis or contact allergy to cosmetics,
4.Hypersensitivity to any cosmetic product, raw material.
5.For whom the Investigator considers that he/she will not be compliant with study procedures.
6.Any clinically significant systemic or cutaneous disease, which may interfere with study treatments or procedures.
7.Subjects on any medical treatment either systemic or topical which may interfere with the performance of the study treatment (presently or in the past 1 month).
8.Subject in an exclusion period or participating in another similar cosmetic or therapeutic trial.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method â?¢Clinical Evaluation using LASI scale.Timepoint: â?¢Day 0, 10 days,20 days and 30 days
- Secondary Outcome Measures
Name Time Method In use skin safety of Clobetasol gel (Clobetasol Propionate USP 0.05% w/w) and Clobetasol Cream (Clobetasol Propionate BP 0.05% w/w).Timepoint: â?¢Day 0, 10 days,20 days and 30 days